600566 济川药业
已收盘 12-05 15:00:00
资讯
新帖
简况
济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,12月1日股价上涨3.05%
证券之星 · 12-01
济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,12月1日股价上涨3.05%
流感高峰期或在下个月!三款流感新药上市 速福达和奥司他韦还缺货吗?
第一财经 · 11-26
流感高峰期或在下个月!三款流感新药上市 速福达和奥司他韦还缺货吗?
济川药业最新公告:拟2500万元-5000万元回购股份
证券之星 · 11-24
济川药业最新公告:拟2500万元-5000万元回购股份
每周股票复盘:济川药业(600566)拟注销17.18万股限制性股票
证券之星 · 11-23
每周股票复盘:济川药业(600566)拟注销17.18万股限制性股票
济川药业(600566)披露2022年限制性股票与股票期权激励计划部分限制性股票回购注销实施公告,11月21日股价下跌1.92%
证券之星 · 11-21
济川药业(600566)披露2022年限制性股票与股票期权激励计划部分限制性股票回购注销实施公告,11月21日股价下跌1.92%
济川药业(600566)披露全资子公司使用闲置募集资金进行现金管理进展,11月18日股价下跌1.54%
证券之星 · 11-18
济川药业(600566)披露全资子公司使用闲置募集资金进行现金管理进展,11月18日股价下跌1.54%
济川药业(600566)披露完成工商变更登记及换发营业执照,10月31日股价上涨1.21%
证券之星 · 10-31
济川药业(600566)披露完成工商变更登记及换发营业执照,10月31日股价上涨1.21%
济川药业(600566)9月30日股东户数4.74万户,较上期增加7.75%
证券之星 · 10-28
济川药业(600566)9月30日股东户数4.74万户,较上期增加7.75%
图解济川药业三季报:第三季度单季净利润同比下降47.19%
证券之星 · 10-27
图解济川药业三季报:第三季度单季净利润同比下降47.19%
每周股票复盘:济川药业(600566)限制行权期为10月23日至27日
证券之星 · 10-19
每周股票复盘:济川药业(600566)限制行权期为10月23日至27日
济川药业(600566)披露限制性股票与股票期权激励计划首次授予股票期权限制行权期间提示性公告,10月14日股价上涨0.85%
证券之星 · 10-14
济川药业(600566)披露限制性股票与股票期权激励计划首次授予股票期权限制行权期间提示性公告,10月14日股价上涨0.85%
每周股票复盘:济川药业(600566)启动股票期权首期行权
证券之星 · 10-12
每周股票复盘:济川药业(600566)启动股票期权首期行权
济川药业(600566)披露2022年股票期权激励计划首次授予第一个行权期自主行权实施公告,10月9日股价上涨1.36%
证券之星 · 10-09
济川药业(600566)披露2022年股票期权激励计划首次授予第一个行权期自主行权实施公告,10月9日股价上涨1.36%
济川药业(600566)163.08万股限售股将于9月30日解禁,占总股本0.18%
证券之星 · 09-30
济川药业(600566)163.08万股限售股将于9月30日解禁,占总股本0.18%
每周股票复盘:济川药业(600566)济川控股质押股份全部解除
证券之星 · 09-21
每周股票复盘:济川药业(600566)济川控股质押股份全部解除
济川药业(600566)披露变更注册资本、取消监事会并修订《公司章程》议案获股东大会通过,9月19日股价下跌0.16%
证券之星 · 09-19
济川药业(600566)披露变更注册资本、取消监事会并修订《公司章程》议案获股东大会通过,9月19日股价下跌0.16%
济川药业业绩连续下滑 重营销轻研发转型之路挑战重重
新浪证券 · 09-18
济川药业业绩连续下滑 重营销轻研发转型之路挑战重重
济川药业(600566.SH)子公司取得利多卡因凝胶贴膏药品注册证书
智通财经 · 09-16
济川药业(600566.SH)子公司取得利多卡因凝胶贴膏药品注册证书
每周股票复盘:济川药业(600566)激励计划行权条件成就
证券之星 · 09-14
每周股票复盘:济川药业(600566)激励计划行权条件成就
济川药业:如有新的回购计划将及时履行信息披露义务
证券日报网 · 09-12
济川药业:如有新的回购计划将及时履行信息披露义务
暂无数据
公司概况
公司名称:
湖北济川药业股份有限公司
所属行业:
医药制造业
上市日期:
2001-08-22
主营业务:
湖北济川药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是小儿豉翘清热颗粒及其糖浆剂型、蒲地蓝消炎口服液、黄龙止咳颗粒、三拗片,健胃消食口服液、硫酸镁钠钾口服用浓溶液及甘海胃康胶囊,妇炎舒胶囊、蛋白琥珀酸铁口服溶液。济川有限荣登“2024中国雇主品牌影响力100强”,荣获“江苏省守合同重信用企业”称号,获评“高质量发展综合奖”“泰兴市2023年度科技创新十佳企业”等四大荣誉,济川有限及董事长曹龙祥荣获“国家科学技术进步二等奖”。
发行价格:
7.80
{"stockData":{"symbol":"600566","market":"SH","secType":"STK","nameCN":"济川药业","latestPrice":27.33,"timestamp":1764918000000,"preClose":27.4,"halted":0,"volume":6537800,"delay":0,"changeRate":-0.0026,"floatShares":918000000,"shares":921000000,"eps":1.7925,"marketStatus":"已收盘","change":-0.07,"latestTime":"12-05 15:00:00","open":27.43,"high":27.55,"low":26.99,"amount":178000000,"amplitude":0.0204,"askPrice":27.33,"askSize":115,"bidPrice":27.32,"bidSize":26,"shortable":0,"etf":0,"ttmEps":1.7925,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":27.4,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":30.14,"lowLimit":24.66,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921215260,"isCdr":false,"pbRate":1.82,"roa":"--","peRate":15.246862,"roe":"7.12%","epsLYR":2.76,"committee":0.016918,"marketValue":25177000000,"turnoverRate":0.0071,"status":1,"floatMarketCap":25092000000},"requestUrl":"/m/hq/s/600566/tweets","defaultTab":"tweets","newsList":[{"id":"2588775364","title":"济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,12月1日股价上涨3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588775364","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588775364?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:22","pubTimestamp":1764598977,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘,济川药业报收于27.06元,较前一交易日上涨3.05%,最新总市值为249.28亿元。该股当日开盘26.86元,最高27.39元,最低26.5元,成交额达4.89亿元,换手率为1.97%。公司近日发布公告称,湖北济川药业股份有限公司于2025年11月24日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,拟用于员工持股计划或股权激励。公司将根据相关规定推进回购工作,并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100036783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0028","BK0188","BK0239","600566","BK0012","BK0077","BK0201"],"gpt_icon":0},{"id":"2586238694","title":"流感高峰期或在下个月!三款流感新药上市 速福达和奥司他韦还缺货吗?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586238694","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586238694?lang=zh_cn&edition=full","pubTime":"2025-11-26 13:35","pubTimestamp":1764135347,"startTime":"0","endTime":"0","summary":"【流感高峰期或在下个月!三款流感新药上市 速福达和奥司他韦还缺货吗?】“我们正全力保障速福达及原研奥司他韦(达菲)在医院端的充足、稳定供应。目前,这两款药物均已在全国实现了广泛的医院准入。今年速福达整体供应量是去年的3倍以上,我们正基于全国各地的实际需求,进行灵活、动态的持续供应调配。同时,如果个别地区突然出现流感疫情大幅上升,罗氏与经销商的保供团队也已经做好了充分的应急预案,将以最快速度响应,确保药品及时送达医疗机构。”罗氏制药这样表示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511263575284928.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511263575284928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["002317","600566","BK0188","BK0201","06887","BK0028","BK1191","BK0187","BK0239","BK0077","BK0012"],"gpt_icon":0},{"id":"2585891463","title":"济川药业最新公告:拟2500万元-5000万元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2585891463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585891463?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:02","pubTimestamp":1763978539,"startTime":"0","endTime":"0","summary":"济川药业(600566.SH)公告称,公司计划使用自有资金以集中竞价交易方式回购部分公司股份,资金总额不低于2500万元(含)且不超过5000万元(含),回购价格不超过38元/股。回购期限为自董事会审议通过之日起12个月内。本次回购的股份将用于实施员工持股计划或股权激励。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400023727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0187","BK0028","BK0239","BK0012","600566","BK0077","BK0188"],"gpt_icon":0},{"id":"2585103630","title":"每周股票复盘:济川药业(600566)拟注销17.18万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103630?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:28","pubTimestamp":1763836094,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,济川药业报收于26.0元,较上周的27.75元下跌6.31%。本周,济川药业11月18日盘中最高价报28.14元。本周关注点公司公告汇总:济川药业拟回购注销171,800股限制性股票,涉及3名离职及5名考核不达标激励对象。湖北济川药业股份有限公司因3名激励对象离职、5名激励对象2022年度个人绩效考核不达标,根据激励计划相关规定,拟回购注销其已获授但尚未解除限售的首次授予限制性股票合计171,800股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0012","600566","BK0187","BK0077","BK0201","BK0028"],"gpt_icon":0},{"id":"2585340149","title":"济川药业(600566)披露2022年限制性股票与股票期权激励计划部分限制性股票回购注销实施公告,11月21日股价下跌1.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585340149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585340149?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:25","pubTimestamp":1763735143,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,济川药业报收于26.0元,较前一交易日下跌1.92%,最新总市值为239.56亿元。公司近日发布公告称,因3名激励对象离职、5名激励对象2022年度个人绩效考核不达标,根据2022年限制性股票与股票期权激励计划相关规定,拟回购注销其已获授但尚未解除限售的首次授予限制性股票合计171,800股。本次回购注销已于2025年9月9日经公司第十届董事会第十七次会议审议通过,并已完成信息披露及债权人公告程序,预计于2025年11月26日完成注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0201","BK0239","BK0187","BK0012","BK0188","600566","BK0028"],"gpt_icon":0},{"id":"2584955337","title":"济川药业(600566)披露全资子公司使用闲置募集资金进行现金管理进展,11月18日股价下跌1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584955337?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:19","pubTimestamp":1763475563,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘,济川药业报收于27.51元,较前一交易日下跌1.54%,最新总市值为253.27亿元。该股当日开盘27.82元,最高28.14元,最低27.41元,成交额达1.82亿元,换手率为0.72%。公司近日发布公告称,其全资子公司济川药业集团有限公司已开立募集资金现金管理专用结算账户,并使用闲置募集资金22,000万元进行现金管理。公司表示,相关事项已经履行董事会、股东大会审议程序,保荐机构亦发表同意意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0188","BK0077","BK0012","BK0239","600566","BK0187","BK0028"],"gpt_icon":0},{"id":"2579645790","title":"济川药业(600566)披露完成工商变更登记及换发营业执照,10月31日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579645790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579645790?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:16","pubTimestamp":1761905817,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,济川药业报收于25.06元,较前一交易日上涨1.21%,最新总市值为230.72亿元。公司近日发布公告称,湖北济川药业股份有限公司已于2025年8月22日和2025年9月19日分别召开第十届董事会第十六次会议及2025年第一次临时股东大会,审议通过《关于变更注册资本、取消监事会并修订<公司章程>的议案》。目前,公司已完成工商变更登记手续,并取得荆州市市场监督管理局换发的营业执照。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100039460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","600566","BK0012","BK0201","BK0188","BK0028","BK0077","BK0239"],"gpt_icon":0},{"id":"2578936344","title":"济川药业(600566)9月30日股东户数4.74万户,较上期增加7.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578936344","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578936344?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:17","pubTimestamp":1761643056,"startTime":"0","endTime":"0","summary":"证券之星消息,近日济川药业披露,截至2025年9月30日公司股东户数为4.74万户,较6月30日增加3405.0户,增幅为7.75%。在中药行业个股中,济川药业股东户数低于行业平均水平,截至9月30日,中药行业平均股东户数为5.36万户。从股价来看,2025年6月30日至2025年9月30日,济川药业区间跌幅为7.63%,在此期间股东户数增加3405.0户,增幅为7.75%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800030737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0239","600566","BK0012","BK0028","BK0077","BK0188","BK0201"],"gpt_icon":0},{"id":"2578142856","title":"图解济川药业三季报:第三季度单季净利润同比下降47.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578142856","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578142856?lang=zh_cn&edition=full","pubTime":"2025-10-27 18:18","pubTimestamp":1761560325,"startTime":"0","endTime":"0","summary":"证券之星消息,济川药业2025年三季报显示,公司主营收入39.32亿元,同比下降32.27%;归母净利润10.22亿元,同比下降46.27%;扣非净利润8.59亿元,同比下降49.43%;其中2025年第三季度,公司单季度主营收入11.83亿元,同比下降33.17%;单季度归母净利润2.98亿元,同比下降47.19%;单季度扣非净利润2.39亿元,同比下降54.0%;负债率16.18%,投资收益1.57亿元,财务费用-5461.28万元,毛利率76.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700028237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600566"],"gpt_icon":0},{"id":"2576041306","title":"每周股票复盘:济川药业(600566)限制行权期为10月23日至27日","url":"https://stock-news.laohu8.com/highlight/detail?id=2576041306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576041306?lang=zh_cn&edition=full","pubTime":"2025-10-19 04:12","pubTimestamp":1760818330,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘,济川药业报收于25.26元,较上周的25.06元上涨0.8%。本周,济川药业10月17日盘中最高价报25.85元。济川药业当前最新总市值232.56亿元,在中药板块市值排名12/67,在两市A股市值排名789/5158。本周关注点公司公告汇总:济川药业首次授予股票期权第一个行权期实际可行权期间为2025年10月15日至2026年9月7日。公司公告汇总:济川药业限制行权期为2025年10月23日至2025年10月27日,期间全部激励对象将限制行权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","600566","BK0201","BK0187","BK0028","BK0077","BK0188"],"gpt_icon":0},{"id":"2575125852","title":"济川药业(600566)披露限制性股票与股票期权激励计划首次授予股票期权限制行权期间提示性公告,10月14日股价上涨0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575125852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575125852?lang=zh_cn&edition=full","pubTime":"2025-10-14 22:59","pubTimestamp":1760453952,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘,济川药业报收于25.03元,较前一交易日上涨0.85%,最新总市值为230.44亿元。公司近日发布公告称,根据相关规定,结合公司2025年第三季度报告披露计划,对2022年限制性股票与股票期权激励计划首次授予股票期权的自主行权时间进行限制。公告显示,首次授予股票期权第一个行权期实际可行权期间为2025年10月15日至2026年9月7日。本次限制行权期为2025年10月23日至2025年10月27日,在此期间全部激励对象将限制行权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400065814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0187","600566","BK0188","BK0077","BK0201","BK0028","BK0239"],"gpt_icon":0},{"id":"2574570204","title":"每周股票复盘:济川药业(600566)启动股票期权首期行权","url":"https://stock-news.laohu8.com/highlight/detail?id=2574570204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574570204?lang=zh_cn&edition=full","pubTime":"2025-10-12 02:10","pubTimestamp":1760206226,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘,济川药业报收于25.06元,较上周的24.32元上涨3.04%。本周,济川药业10月10日盘中最高价报25.08元。济川药业当前最新总市值230.72亿元,在中药板块市值排名12/67,在两市A股市值排名825/5158。本周关注点公司公告汇总:济川药业首次授予股票期权第一个行权期启动,行权价格20.74元/份,行权数量1,714,800份。公司公告汇总湖北济川药业股份有限公司发布关于2022年限制性股票与股票期权激励计划首次授予股票期权第一个行权期自主行权实施的公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","600566","BK0239","BK0187","BK0012","BK0201","BK0077"],"gpt_icon":0},{"id":"2574444161","title":"济川药业(600566)披露2022年股票期权激励计划首次授予第一个行权期自主行权实施公告,10月9日股价上涨1.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574444161","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574444161?lang=zh_cn&edition=full","pubTime":"2025-10-09 23:20","pubTimestamp":1760023226,"startTime":"0","endTime":"0","summary":"截至2025年10月9日收盘,济川药业报收于24.65元,较前一交易日上涨1.36%,最新总市值为226.94亿元。近日,湖北济川药业股份有限公司发布关于2022年限制性股票与股票期权激励计划首次授予股票期权第一个行权期自主行权实施的公告。首次授予日为2022年9月8日,第一个行权期行权条件已成就,公司层面业绩考核目标已完成,净利润为21.83亿元,BD产品引进4个,行权系数为100%。行权时间为2025年10月15日至2026年9月7日之间的交易日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900035142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0201","600566","BK0188","BK0077","BK0012","BK0187","BK0239"],"gpt_icon":0},{"id":"2571874362","title":"济川药业(600566)163.08万股限售股将于9月30日解禁,占总股本0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571874362","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571874362?lang=zh_cn&edition=full","pubTime":"2025-09-30 08:05","pubTimestamp":1759190755,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,济川药业于9月30日将有163.08万股限售股份解禁,为公司股权激励限售股份,占公司总股本0.18%。本次解禁后,公司还有328.17万股限售股份,占总股本0.36%。济川药业主营业务:药品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000005936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0187","600566","BK0188","BK0077","BK0201","BK0028","BK0239"],"gpt_icon":0},{"id":"2569249326","title":"每周股票复盘:济川药业(600566)济川控股质押股份全部解除","url":"https://stock-news.laohu8.com/highlight/detail?id=2569249326","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569249326?lang=zh_cn&edition=full","pubTime":"2025-09-21 05:12","pubTimestamp":1758402739,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,济川药业报收于25.46元,较上周的25.92元下跌1.77%。本周关注点公司公告汇总:控股股东济川控股所持公司股份质押全部解除,剩余被质押股份数量为0。本次解除质押股份43,000,000股,占其所持股份比例10.32%,占公司总股本比例4.67%,解除质押时间为2025年9月12日。本次解除质押后,济川控股持有的公司股份已不存在被质押的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100001355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0201","BK0077","BK0187","BK0028","01420","BK0188","BK0239","BK1148","600566"],"gpt_icon":0},{"id":"2568170261","title":"济川药业(600566)披露变更注册资本、取消监事会并修订《公司章程》议案获股东大会通过,9月19日股价下跌0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568170261","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568170261?lang=zh_cn&edition=full","pubTime":"2025-09-19 22:42","pubTimestamp":1758292947,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘,济川药业报收于25.46元,较前一交易日下跌0.16%,最新总市值为234.4亿元。该股当日开盘25.46元,最高25.58元,最低25.29元,成交额达7778.51万元,换手率为0.33%。其中,《关于变更注册资本、取消监事会并修订〈公司章程〉的议案》等前三项为特别决议议案,已获得出席会议股东所持有效表决权的三分之二以上通过;其余三项为普通决议议案,已获得过半数通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091900037485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0077","BK0201","600566","BK0012","BK0028","BK0187"],"gpt_icon":0},{"id":"2568764214","title":"济川药业业绩连续下滑 重营销轻研发转型之路挑战重重","url":"https://stock-news.laohu8.com/highlight/detail?id=2568764214","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568764214?lang=zh_cn&edition=full","pubTime":"2025-09-18 18:42","pubTimestamp":1758192120,"startTime":"0","endTime":"0","summary":" 近日,济川药业披露2025年半年度报告。财务数据显示,继2024年营收、净利润出现自2021年以来首次双降后,公司2025年上半年的业绩下滑幅度进一步扩大。曾经的王牌产品蒲地蓝消炎口服液和小儿豉翘清热颗粒陷入增长困境,叠加医药集采政策的持续影响,济川药业的发展前景或面临挑战。 回顾历史数据,济川药业的业绩波动均与这两大单品密切相关。 从研发费用看,济川药业长期以来存在的重营销、轻研发问题依然突出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-09-18/doc-infqxmri8770532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0201","BK0187","BK0028","BK0077","600566","BK0239","BK0012"],"gpt_icon":0},{"id":"2567617090","title":"济川药业(600566.SH)子公司取得利多卡因凝胶贴膏药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2567617090","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567617090?lang=zh_cn&edition=full","pubTime":"2025-09-16 16:32","pubTimestamp":1758011557,"startTime":"0","endTime":"0","summary":"智通财经APP讯,济川药业(600566.SH)公告,公司全资子公司陕西东科制药有限责任公司(简称“陕西东科”)收到国家药品监督管理局核准签发的利多卡因凝胶贴膏《药品注册证书》。利多卡因是一种酰胺类局部麻醉剂,通过抑制神经冲动发生与传导所需的离子通道而起到稳定神经细胞膜作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1345782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600566","BK0188","BK0201","BK0028","BK0187","BK0239","BK0077","BK0012"],"gpt_icon":0},{"id":"2567513646","title":"每周股票复盘:济川药业(600566)激励计划行权条件成就","url":"https://stock-news.laohu8.com/highlight/detail?id=2567513646","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567513646?lang=zh_cn&edition=full","pubTime":"2025-09-14 05:04","pubTimestamp":1757797455,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘,济川药业报收于25.92元,较上周的25.72元上涨0.78%。公司公告汇总湖北济川药业股份有限公司董事会薪酬与考核委员会确认,2022年限制性股票与股票期权激励计划首次授予部分第一个解除限售期解除限售条件及第一个行权期行权条件已成就。58名激励对象可解除限售股份占公司总股本0.18%,60名激励对象可行权期权占公司总股本0.19%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400001185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0201","BK0077","BK0187","BK0028","BK0188","BK0239","600566"],"gpt_icon":0},{"id":"2566977430","title":"济川药业:如有新的回购计划将及时履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2566977430","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566977430?lang=zh_cn&edition=full","pubTime":"2025-09-12 21:10","pubTimestamp":1757682600,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n证券日报网讯济川药业9月12日在互动平台回答投资者提问时表示,公司如有新的回购计划,将严格按照相关规定及时履行信息披露义务。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-12/doc-infqhcie9177333.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-12/doc-infqhcie9177333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0187","600566","BK0012","BK0201","BK0188","BK0028","BK0077","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765150225509,"stockEarnings":[{"period":"1week","weight":0.0407},{"period":"1month","weight":0.0854},{"period":"3month","weight":0.0626},{"period":"6month","weight":0.0755},{"period":"1year","weight":0.004},{"period":"ytd","weight":0.0127}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北济川药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47359人(较上一季度增加7.75%)","perCapita":"19386股","listingDate":"2001-08-22","address":"湖北省荆州市沙市区园林路时尚豪庭602室","registeredCapital":"92121万元","survey":" 湖北济川药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是小儿豉翘清热颗粒及其糖浆剂型、蒲地蓝消炎口服液、黄龙止咳颗粒、三拗片,健胃消食口服液、硫酸镁钠钾口服用浓溶液及甘海胃康胶囊,妇炎舒胶囊、蛋白琥珀酸铁口服溶液。济川有限荣登“2024中国雇主品牌影响力100强”,荣获“江苏省守合同重信用企业”称号,获评“高质量发展综合奖”“泰兴市2023年度科技创新十佳企业”等四大荣誉,济川有限及董事长曹龙祥荣获“国家科学技术进步二等奖”。","listedPrice":7.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供济川药业(600566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"济川药业,600566,济川药业股票,济川药业股票老虎,济川药业股票老虎国际,济川药业行情,济川药业股票行情,济川药业股价,济川药业股市,济川药业股票价格,济川药业股票交易,济川药业股票购买,济川药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供济川药业(600566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}